NKTX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Nkarta Inc

NASDAQ | NKTX

2.24

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$153.41M

Market Cap

-

P/E Ratio

-1.46

EPS

$4.54

52 Week High

$1.31

52 Week Low

HEALTHCARE

Sector

NKTX Chart

Recent Chart
Price Action

NKTX Technicals

Tags:

NKTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$9.2M
Total Revenue $0
Cost Of Revenue $9.2M
Costof Goods And Services Sold $9.2M
Operating Income -$128M
Selling General And Administrative $31M
Research And Development $97M
Operating Expenses $128M
Investment Income Net -
Net Interest Income $19M
Interest Income $19M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $9.2M
Income Before Tax -$109M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$109M
Comprehensive Income Net Of Tax -
Ebit -$109M
Ebitda -$100M
Net Income -$109M

Revenue & Profitability

Earnings Performance

NKTX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $501M
Total Current Assets $273M
Cash And Cash Equivalents At Carrying Value $28M
Cash And Short Term Investments $28M
Inventory -
Current Net Receivables $200K
Total Non Current Assets $228M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $110M
Short Term Investments $239M
Other Current Assets $5.8M
Other Non Current Assets -
Total Liabilities $93M
Total Current Liabilities $19M
Current Accounts Payable $638K
Deferred Revenue -
Current Debt -
Short Term Debt $6.1M
Total Non Current Liabilities $74M
Capital Lease Obligations $80M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $80M
Other Current Liabilities $12M
Other Non Current Liabilities $87K
Total Shareholder Equity $408M
Treasury Stock -
Retained Earnings -$544M
Common Stock $7K
Common Stock Shares Outstanding $68M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$100M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.2M
Capital Expenditures $4.4M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$130M
Cashflow From Financing $226M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$109M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$9.2M
Total Revenue $0
Cost Of Revenue $9.2M
Costof Goods And Services Sold $9.2M
Operating Income -$128M
Selling General And Administrative $31M
Research And Development $97M
Operating Expenses $128M
Investment Income Net -
Net Interest Income $19M
Interest Income $19M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $9.2M
Income Before Tax -$109M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$109M
Comprehensive Income Net Of Tax -
Ebit -$109M
Ebitda -$100M
Net Income -$109M

NKTX News

NKTX Profile

Nkarta Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Nkarta, Inc. is an innovative clinical-stage biopharmaceutical company based in South San Francisco, California, focused on the development of advanced cell therapies aimed at transforming cancer treatment. By leveraging its proprietary technology platform, Nkarta is pioneering novel therapies that harness the power of the immune system to target and eliminate cancer cells. With a robust pipeline of product candidates in various stages of clinical development, Nkarta is poised to address unmet medical needs in oncology and contribute to the future of cancer care.

VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
ELBM
+334.95%
$7.17
PLUG
+13.44%
$3.87
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVDA
+2.25%
$187.29
NVTS
+23.51%
$10.16
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
JOBY
+2.61%
$16.70
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
F
+0.96%
$11.52
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
USAR
+17.01%
$38.15
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
RR
+7.85%
$6.38
SOUN
+10.77%
$19.23
WBD
-3.22%
$17.10
MP
+23.30%
$96.60
ABAT
+33.25%
$8.99
NAK
+26.47%
$2.56
RMBL
+60.50%
$3.21
IREN
+8.04%
$64.58
ADD
-25.47%
$0.05
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
EPWK
-11.00%
$0.08
NAKA
-4.05%
$0.83
UAMY
+37.67%
$16.80
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
PFE
+0.10%
$24.80
ADAP
-0.70%
$0.18
BMNR
+7.40%
$56.35
QUBT
+10.49%
$21.01
GDXD
-12.99%
$0.74
SNAP
+3.14%
$8.02
XCH
+119.76%
$1.81
CJET
-14.93%
$0.12
MRVL
-5.52%
$85.61
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
RF
+1.84%
$24.60
HOOD
+1.03%
$140.40
HPE
+2.76%
$25.07
PMAX
+75.28%
$4.54
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
KDP
+3.02%
$26.60
RGTZ
-42.68%
$10.66
T
-1.10%
$25.58
VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
ELBM
+334.95%
$7.17
PLUG
+13.44%
$3.87
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVDA
+2.25%
$187.29
NVTS
+23.51%
$10.16
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
JOBY
+2.61%
$16.70
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
F
+0.96%
$11.52
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
USAR
+17.01%
$38.15
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
RR
+7.85%
$6.38
SOUN
+10.77%
$19.23
WBD
-3.22%
$17.10
MP
+23.30%
$96.60
ABAT
+33.25%
$8.99
NAK
+26.47%
$2.56
RMBL
+60.50%
$3.21
IREN
+8.04%
$64.58
ADD
-25.47%
$0.05
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
EPWK
-11.00%
$0.08
NAKA
-4.05%
$0.83
UAMY
+37.67%
$16.80
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
PFE
+0.10%
$24.80
ADAP
-0.70%
$0.18
BMNR
+7.40%
$56.35
QUBT
+10.49%
$21.01
GDXD
-12.99%
$0.74
SNAP
+3.14%
$8.02
XCH
+119.76%
$1.81
CJET
-14.93%
$0.12
MRVL
-5.52%
$85.61
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
RF
+1.84%
$24.60
HOOD
+1.03%
$140.40
HPE
+2.76%
$25.07
PMAX
+75.28%
$4.54
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
KDP
+3.02%
$26.60
RGTZ
-42.68%
$10.66
T
-1.10%
$25.58
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.